恶性黑色素瘤的预后特征及对咪唑甲酰胺的反应 - Suppr

Suppr

超能文献

Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma.

作者信息

Nathanson L, Wolter J, Horton J, Colsky J, Shnider B I, Schilling A

出版信息

Clin Pharmacol Ther. 1971 Nov-Dec;12(6):955-62. doi: 10.1002/cpt1971126955.

DOI:10.1002/cpt1971126955

PMID:5134998

Abstract

摘要

相似文献

Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma.

Clin Pharmacol Ther. 1971 Nov-Dec;12(6):955-62. doi: 10.1002/cpt1971126955.

Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.

Cancer Chemother Rep. 1972 Oct;56(5):671-7.

Chemotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and dactinomycin.

Cancer. 1973 Oct;32(4):756-60. doi: 10.1002/1097-0142(197310)32:4<756::aid-cncr2820320404>3.0.co;2-6.

Study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with disseminated melanoma.

Cancer Chemother Rep. 1973 Feb;57(1):83-4.

Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.

Cancer. 1973 Oct;32(4):749-55. doi: 10.1002/1097-0142(197310)32:4<749::aid-cncr2820320403>3.0.co;2-1.

Dacarbazine for malignant melanoma.

Med Lett Drugs Ther. 1974 Mar 15;16(6):27-8.

Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide.

Cancer. 1972 Dec;30(6):1632-8. doi: 10.1002/1097-0142(197212)30:6<1632::aid-cncr2820300632>3.0.co;2-s.

Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).

Cancer Chemother Rep. 1974 Sep-Oct;58(5 Pt 1):753-4.

Evaluation of 1-(2-chloroethyl-3-4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU, NSC 95441) versus combined imidazole carboxamide (NSC 45338) and vincristine (NSC 67574) in palliation of disseminated malignant melanoma.

Cancer. 1974 Mar;33(3):615-8. doi: 10.1002/1097-0142(197403)33:3<615::aid-cncr2820330304>3.0.co;2-f.

5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.

Eur J Cancer (1965). 1972 Feb;8(1):85-92. doi: 10.1016/0014-2964(72)90087-4.

引用本文的文献

More than Just Skin-Deep: A Review of Imaging's Role in Guiding CAR T-Cell Therapy for Advanced Melanoma.

Diagnostics (Basel). 2023 Mar 5;13(5):992. doi: 10.3390/diagnostics13050992.

Translating Molecules into Imaging-The Development of New PET Tracers for Patients with Melanoma.

Diagnostics (Basel). 2022 Apr 29;12(5):1116. doi: 10.3390/diagnostics12051116.

WITHDRAWN: Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018 Feb 7;2(2):CD001215. doi: 10.1002/14651858.CD001215.pub2.

State of melanoma: an historic overview of a field in transition.

Hematol Oncol Clin North Am. 2014 Jun;28(3):415-35. doi: 10.1016/j.hoc.2014.02.010.

Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.

Med Oncol. 1995 Mar;12(1):35-40. doi: 10.1007/BF01571406.

Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.

Cancer Chemother Pharmacol. 1982;9(2):103-9. doi: 10.1007/BF00265388.

Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU).

Ann Surg. 1974 Aug;180(2):167-74. doi: 10.1097/00000658-197408000-00007.

Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.

Cancer Chemother Pharmacol. 1990;27(2):81-4. doi: 10.1007/BF00689087.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验